ResMed (RMD)
(Delayed Data from NYSE)
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), led by strategic alliances and new product launches.
Boston Scientific (BSX) Rides on Emerging Markets, MedSurg
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
by Zacks Equity Research
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
Globus Medical (GMED) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.
Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
CVS Health (CVS) Expands Food and Beverage Line With New Launch
by Zacks Equity Research
CVS Health's (CVS) Well Market brand offers a blend of mouthwatering flavors and nutritious options, expertly crafted and taste-tested by food enthusiasts.
Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes
by Zacks Equity Research
Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.
Here's Why You Should Buy Haemonetics (HAE) Stock Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade
by Zacks Equity Research
Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.
Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?
by Zacks Equity Research
Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.
Wall Street Analysts See ResMed (RMD) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in ResMed (RMD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Here's Why Investors Should Buy ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.
Boston Scientific (BSX) mCRM System Study Outcome Favorable
by Zacks Equity Research
Boston Scientific (BSX) mCRM System is designed to communicate wirelessly and coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy.
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Maravai (MRVI) Advances in RNA Research With New Collaboration
by Zacks Equity Research
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
What Makes ResMed (RMD) a New Strong Buy Stock
by Zacks Equity Research
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Align Technology (ALGN) Gains From Innovation, Global Expansion
by Zacks Equity Research
In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.
Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls
by Zacks Equity Research
Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.
Labcorp (LH) to Assess Preeclampsia Risk With New Test
by Zacks Equity Research
Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), owing to strategic acquisitions and potential in Henry Schein One.
Here is Why Growth Investors Should Buy ResMed (RMD) Now
by Zacks Equity Research
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.
QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification
by Zacks Equity Research
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.